Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading
cause of cancer‐related death worldwide. HCC exhibits strong inter‐tumor heterogeneity …

Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-
L1) inhibitors have demonstrated commendable efficacy in some patients with advanced …

Objectives This study aimed to investigate the efficacy and safety of transarterial
chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting …

Background The synergistic effect of locoregional therapy in combination with systemic
therapy as a conversion therapy for unresectable hepatocellular carcinoma (uHCC) is …

Background To assess the perioperative safety, oncological outcomes, and determinants
influencing the oncological outcomes of salvage liver resection for initially unresectable …

Purpose The current therapeutic strategies for high-risk, unresectable hepatocellular
carcinoma (HCC) patients demonstrate suboptimal outcomes. This study aimed to assess …

Disulfidoptosis and ferroptosis are two distinct programmed cell death pathways that have
garnered considerable attention due to their potential as therapeutic targets. However …

Objective This study aimed to access hepatitis B virus (HBV) reactivation and its effect on
survival in HBV-related hepatocarcinoma (HCC) patients who underwent transarterial …

In this work, a promising treatment strategy for triggering robust antitumor immune
responses in transarterial chemoembolization of hepatocellular carcinoma (HCC) is …

Purpose In the study, patients with unresectable hepatocellular carcinoma (uHCC) were
treated with either transcatheter chemoembolization (TACE) combined with lenvatinib and …